Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

BACKGROUND: Malignant cells of classical Hodgkin lymphoma (cHL) are characterised by genetic alterations at the 9p24·1 locus. This leads to overexpression of the programmed death 1 (PD-1) ligands and enables tumour cells to evade immune surveillance. A phase 1b study showed that nivolumab, a PD-1-bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Younes, Anas, Santoro, Armando, Shipp, Margaret, Zinzani, Pier Luigi, Timmerman, John M, Ansell, Stephen, Armand, Philippe, Fanale, Michelle, Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B, Collins, Graham, Savage, Kerry J, Trneny, Marek, Kato, Kazunobu, Farsaci, Benedetto, Parker, Susan M, Rodig, Scott, Roemer, Margaretha GM, Ligon, Azra H, Engert, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541855/
https://www.ncbi.nlm.nih.gov/pubmed/27451390
http://dx.doi.org/10.1016/S1470-2045(16)30167-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541855/
https://www.ncbi.nlm.nih.gov/pubmed/27451390
http://dx.doi.org/10.1016/S1470-2045(16)30167-X

Ejemplares similares